The Effect of Losartan on the Recoverability of Renal Function in Anuric and Oliguric Patients With Unilateral Obstructed Kidney
NCT04278495 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96
Last updated 2020-02-20
Summary
Previous experimental studies concluded that angiotensin receptor blockers can ameliorate the harmful inflammatory and histological changes after relief of obstruction. Nevertheless, these witnessed effects have not been yet translated into the clinical practice.
Conditions
- Losartan Adverse Reaction
- Uropathy
- Uropathy Obstructive
Interventions
- DRUG
-
Cozaar (Losartan Potassium 25mg)
Cozaar (Losartan Potassium 25mg)
- DRUG
-
Placebo
Sponsors & Collaborators
-
Mansoura University
lead OTHER
Principal Investigators
-
Ahmed Shokier · Mansoura University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-09-01
- Primary Completion
- 2018-12-01
- Completion
- 2018-12-01
Countries
- Egypt
Study Locations
More Related Trials
-
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
NCT07074418 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure
NCT00527059 ·Status: UNKNOWN ·Phase: PHASE4
-
Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies
NCT05402397 ·Status: COMPLETED ·Phase: PHASE4
-
Losartan in Decompensated Heart Failure
NCT01857999 ·Status: COMPLETED ·Phase: PHASE4
-
Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)
NCT00237588 ·Status: COMPLETED ·Phase: PHASE4
-
Improving Outcomes in Patients With Kidney Disease Due to Diabetes
NCT00381134 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Atorvastatin on Renal Function in Healthy Subjects During Normal and High Sodium Intake
NCT00678184 ·Status: COMPLETED ·Phase: PHASE4
-
Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1
NCT03357653 ·Status: UNKNOWN ·Phase: PHASE3
-
Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan
NCT06491940 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients
NCT00530595 ·Status: COMPLETED ·Phase: NA
-
A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers
NCT01314898 ·Status: COMPLETED ·Phase: PHASE1
-
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
NCT03596957 ·Status: UNKNOWN ·Phase: PHASE4
-
Bosentan Use in Patients With Diabetic Nephropathy
NCT00638131 ·Status: TERMINATED ·Phase: PHASE3
-
Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment
NCT02653014 ·Status: COMPLETED ·Phase: PHASE1
-
CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
NCT01678794 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tolvaptan-Octreotide LAR Combination in ADPKD
NCT03541447 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
NCT04968184 ·Status: TERMINATED ·Phase: PHASE3
-
Aliskiren in Patients With Idiopathic Membranous Nephropathy
NCT01093781 ·Status: WITHDRAWN ·Phase: NA
-
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
NCT01424319 ·Status: COMPLETED ·Phase: PHASE2
-
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
NCT00732771 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Diuretics in Kidney Disease
NCT04542304 ·Status: TERMINATED ·Phase: PHASE2
-
Loop Diuretics in Chronic Kidney Disease
NCT00478543 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
NCT06150924 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986 ·Status: RECRUITING ·Phase: PHASE2
-
Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure
NCT01549158 ·Status: TERMINATED ·Phase: PHASE4